CN101107253A - 有丝分裂驱动蛋白抑制剂 - Google Patents

有丝分裂驱动蛋白抑制剂 Download PDF

Info

Publication number
CN101107253A
CN101107253A CNA2006800025407A CN200680002540A CN101107253A CN 101107253 A CN101107253 A CN 101107253A CN A2006800025407 A CNA2006800025407 A CN A2006800025407A CN 200680002540 A CN200680002540 A CN 200680002540A CN 101107253 A CN101107253 A CN 101107253A
Authority
CN
China
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800025407A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·科尔曼
G·D·哈特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101107253A publication Critical patent/CN101107253A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNA2006800025407A 2005-01-19 2006-01-13 有丝分裂驱动蛋白抑制剂 Pending CN101107253A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64493305P 2005-01-19 2005-01-19
US60/644,933 2005-01-19

Publications (1)

Publication Number Publication Date
CN101107253A true CN101107253A (zh) 2008-01-16

Family

ID=36692758

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800025407A Pending CN101107253A (zh) 2005-01-19 2006-01-13 有丝分裂驱动蛋白抑制剂

Country Status (7)

Country Link
US (1) US20080102068A1 (enExample)
EP (1) EP1856128A4 (enExample)
JP (1) JP4545196B2 (enExample)
CN (1) CN101107253A (enExample)
AU (1) AU2006206738A1 (enExample)
CA (1) CA2595127A1 (enExample)
WO (1) WO2006078574A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN114845719A (zh) * 2019-12-18 2022-08-02 蒙特利尔大学 作为抗癌化合物的cullin 3连接蛋白kbtbd4的调节剂
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR080893A1 (es) * 2010-04-15 2012-05-16 Novartis Ag Compuestos de triazol como inhibidores de ksp
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686120A3 (en) * 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP4467979B2 (ja) * 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
EP1465896A4 (en) * 2001-12-06 2006-01-11 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
CA2468266A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
DE60222302T2 (de) * 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
EP1551962A4 (en) * 2002-07-08 2007-08-01 Merck & Co Inc MITOTIC KINESIN BINDING CENTER
US20070149500A1 (en) * 2003-01-17 2007-06-28 Han-Jie Zhou Compounds, compositions, and methods
DE602004021477D1 (de) * 2003-03-07 2009-07-23 Astrazeneca Ab Kondensierte heterocyclen und deren verwendungen

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715634A (zh) * 2016-09-14 2019-05-03 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US11220517B2 (en) 2016-09-14 2022-01-11 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109715634B (zh) * 2016-09-14 2022-09-27 詹森药业有限公司 Menin-mll相互作用的稠合二环抑制剂
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
US11530226B2 (en) 2016-12-15 2022-12-20 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN114845719A (zh) * 2019-12-18 2022-08-02 蒙特利尔大学 作为抗癌化合物的cullin 3连接蛋白kbtbd4的调节剂
US12473295B2 (en) 2019-12-19 2025-11-18 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives

Also Published As

Publication number Publication date
WO2006078574A3 (en) 2007-03-22
EP1856128A2 (en) 2007-11-21
WO2006078574A2 (en) 2006-07-27
CA2595127A1 (en) 2006-07-27
AU2006206738A1 (en) 2006-07-27
US20080102068A1 (en) 2008-05-01
EP1856128A4 (en) 2009-12-23
JP4545196B2 (ja) 2010-09-15
JP2008527038A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
CN101107253A (zh) 有丝分裂驱动蛋白抑制剂
US20070060601A1 (en) Mitotic kinesin inhibitors
CN101155583B (zh) 有丝分裂驱动蛋白的抑制剂
CN101084194A (zh) 有丝分裂驱动蛋白抑制剂
US7625912B2 (en) Mitotic kinesin inhibitors
US7632839B2 (en) Mitotic kinesin inhibitors
US7625936B2 (en) Mitotic kinesin inhibitors
US20090124641A1 (en) Mitotic Kinesin Inhibitors
CN101005837A (zh) 有丝分裂驱动蛋白抑制剂
US7553838B2 (en) Mitotic kinesin inhibitors
CN1980662A (zh) 有丝分裂驱动蛋白抑制剂
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
US20070149553A1 (en) Mitotic kinesin inhibitors
US7732472B2 (en) Mitotic kinesin inhibitors
JP2008505090A (ja) 有糸分裂キネシン阻害剤のプロドラッグ
CN1980663A (zh) 有丝分裂驱动蛋白抑制剂的前体药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080116